$-0.72 EPS Expected for Sienna Biopharmaceuticals, Inc. (SNNA)

May 17, 2018 - By Ash Ash

Analysts expect Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) to report $-0.72 EPS on June, 21.After having $-0.56 EPS previously, Sienna Biopharmaceuticals, Inc.’s analysts see 28.57 % EPS growth. The stock decreased 1.43% or $0.21 during the last trading session, reaching $14.45. About 64,126 shares traded. Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) has 0.00% since May 18, 2017 and is . It has underperformed by 11.55% the S&P500.

Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes topical products for medical dermatology and aesthetics markets in North America. The company has market cap of $291.69 million. The companyÂ’s lead product candidates include SNA-120, a TrkA inhibitor, which is in Phase 2b clinical development for the treatment of pruritus, itch, and neurogenic inflammation associated with psoriasis; and SNA-125, a dual JAK3/TrkA inhibitor that is in pre-clinical study for the treatment of atopic dermatitis, psoriasis, and pruritus. It currently has negative earnings. It also develops SNA-001, a photoparticle therapy, which is in pivotal clinical trials for the treatment of acne vulgaris and the reduction of unwanted light-pigmented hair.

More recent Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) news were published by: Nasdaq.com which released: “Sienna Biopharmaceuticals to Present SNA-125 Pre-Clinical Psoriasis Data as Late-Breaker at the International …” on May 16, 2018. Also Globenewswire.com published the news titled: “Sienna Biopharmaceuticals to Present at BAML Health Care Conference” on May 11, 2018. Globenewswire.com‘s news article titled: “Sienna Biopharmaceuticals Reports First Quarter 2018 Financial Results” with publication date: May 14, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: